<DOC>
	<DOCNO>NCT02392156</DOCNO>
	<brief_summary>The primary objective study evaluate effectiveness prophylactic treatment recombinant Factor VIII Fc fusion protein ( rFVIIIFc ) recombinant Factor IX Fc fusion protein ( rFIXFc ) therapy assess patient treatment burden health economic outcome maintain disease control males hemophilia A B .</brief_summary>
	<brief_title>Fc factOrs Real-World hemophiliA Patient-ReporteD Outcomes</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Key Have medically document diagnosis hemophilia A B treat prophylactically factor replacement product design prolonged halflife satisfy therapeutic indication rFVIIIFc/rFIXFc per approve local label Have least 50 prior exposure day ( EDs ) combination factor replacement product Have document prestudy data available confirm fulfillment eligibility criterion Have measurable inhibitor activity sample obtain within 4 week prior Baseline visit , absence clinical sign symptom decrease response current factor replacement product Key Have diagnosis bleed disorder hemophilia A hemophilia B additional coagulation disorder ( ) addition hemophilia A hemophilia B Have prior history anaphylaxis associate factor VIII ( FVIII ) / factor IX ( FIX ) intravenous immunoglobin administration Had inhibitor within 5 year Baseline visit . Note : A family history inhibitor exclude patient . Past current treatment factor replacement product prolonged halflife , include Fc product , treatment hemophilia NOTE : Other Protocol Defined Inclusion/ Exclusion Criteria May Apply .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>